Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Satralizumab reduces risk of severe NMOSD relapse

Key clinical point: Patients with NMOSD who receive treatment with satralizumab are less likely to have a severe relapse, compared with controls.

Major finding: The proportion of severe relapses was 19% in the satralizumab group and 35% in the placebo group.

Study details: A pooled intention-to-treat analysis of data for 178 participants in two studies.

Disclosures: Chugai/Roche funded the study. Dr. Kleiter has received compensation for consulting, speaking, or serving on advisory boards for Alexion, Biogen, Celgene, Merck, and Roche.

Citation:

Kleiter I, et al. MSVirtual2020. Abstract FC01.03.